Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib vs Methotrexate in Diffuse Cutaneous Systemic Sclerosis
NCT07472166Phase 4Completed
- Sponsor
- Bangabandhu Sheikh Mujib Medical University
- Start
- Dec 2024
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of tofacitinib oral solution in systemic sclerosis (SSc) (2 arms), sponsored by Bangabandhu Sheikh Mujib Medical University. Primary endpoint: Modified Rodnan Skin Score at 24 weeks. Started Dec 2024; status: completed.
02
Drugs
tofacitinib oral solution
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT07472166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07472166.